FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947405510> ?p ?o ?g. }

• W2947405510 endingPage "4965" @default.
• W2947405510 startingPage "4955" @default.
• W2947405510 abstract "Abstract Purpose: mAbs including cetuximab can induce antibody-dependent cellular cytotoxicity (ADCC) and cytokine production mediated via innate immune cells with the ability to recognize mAb-coated tumors. Preclinical modeling has shown that costimulation of natural killer (NK) cells via the Fc receptor and the IL12 receptor promotes NK-cell–mediated ADCC and production of cytokines. Patients and Methods: This phase I/II trial evaluated the combination of cetuximab with IL12 for the treatment of EGFR-expressing head and neck cancer. Treatment consisted of cetuximab 500 mg/m2 i.v. every 2 weeks with either 0.2 mcg/kg or 0.3 mcg/kg IL12 s.c. on days 2 and 5 of the 2-week cycle, beginning with cycle 2. Correlative studies from blood draws obtained prior to treatment and during therapy included measurement of ADCC, serum cytokine, and chemokine analysis, determination of NK cell FcγRIIIa polymorphisms, and an analysis of myeloid-derived suppressor cell (MDSC) frequency in peripheral blood. Results: The combination of cetuximab and IL12 was well tolerated. No clinical responses were observed, however, 48% of patients exhibited prolonged progression-free survival (PFS; average of 6.5 months). Compared with patients that did not exhibit clinical benefit, patients with PFS &gt;100 days exhibited increased ADCC as therapy continued compared with baseline, greater production of IFNγ, IP-10, and TNFα at the beginning of cycle 8 compared with baseline values and had a predominance of monocytic MDSCs versus granulocytic MDSCs prior to therapy. Conclusions: Further investigation of IL12 as an immunomodulatory agent in combination with cetuximab in head and neck squamous cell carcinoma is warranted." @default.
• W2947405510 created "2019-06-07" @default.
• W2947405510 creator A5000921376 @default.
• W2947405510 creator A5005521067 @default.
• W2947405510 creator A5006315280 @default.
• W2947405510 creator A5015153331 @default.
• W2947405510 creator A5015697739 @default.
• W2947405510 creator A5024285638 @default.
• W2947405510 creator A5028975540 @default.
• W2947405510 creator A5029344965 @default.
• W2947405510 creator A5033505983 @default.
• W2947405510 creator A5043871151 @default.
• W2947405510 creator A5049192022 @default.
• W2947405510 creator A5053484014 @default.
• W2947405510 creator A5054522457 @default.
• W2947405510 creator A5054983553 @default.
• W2947405510 creator A5056489446 @default.
• W2947405510 creator A5060897770 @default.
• W2947405510 creator A5063621818 @default.
• W2947405510 creator A5070081712 @default.
• W2947405510 creator A5073968481 @default.
• W2947405510 creator A5075551888 @default.
• W2947405510 creator A5079526097 @default.
• W2947405510 creator A5080361449 @default.
• W2947405510 creator A5082352583 @default.
• W2947405510 creator A5083608306 @default.
• W2947405510 date "2019-08-15" @default.
• W2947405510 modified "2023-10-15" @default.
• W2947405510 title "A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma" @default.
• W2947405510 cites W1493141130 @default.
• W2947405510 cites W1499740654 @default.
• W2947405510 cites W1502100938 @default.
• W2947405510 cites W1517571912 @default.
• W2947405510 cites W1821988420 @default.
• W2947405510 cites W1838340609 @default.
• W2947405510 cites W1963665993 @default.
• W2947405510 cites W1969814796 @default.
• W2947405510 cites W1977103256 @default.
• W2947405510 cites W1988401045 @default.
• W2947405510 cites W1994040396 @default.
• W2947405510 cites W2006073656 @default.
• W2947405510 cites W2009043731 @default.
• W2947405510 cites W2010034291 @default.
• W2947405510 cites W2027536435 @default.
• W2947405510 cites W2030177319 @default.
• W2947405510 cites W2036546477 @default.
• W2947405510 cites W2038918212 @default.
• W2947405510 cites W2039950956 @default.
• W2947405510 cites W2043642585 @default.
• W2947405510 cites W2045814042 @default.
• W2947405510 cites W2055082742 @default.
• W2947405510 cites W2057965214 @default.
• W2947405510 cites W2060974366 @default.
• W2947405510 cites W2083786790 @default.
• W2947405510 cites W2089257078 @default.
• W2947405510 cites W2097328301 @default.
• W2947405510 cites W2098394317 @default.
• W2947405510 cites W2100510996 @default.
• W2947405510 cites W2112845420 @default.
• W2947405510 cites W2114666853 @default.
• W2947405510 cites W2118991777 @default.
• W2947405510 cites W2120068217 @default.
• W2947405510 cites W2121136366 @default.
• W2947405510 cites W2125662786 @default.
• W2947405510 cites W2126240154 @default.
• W2947405510 cites W2126855223 @default.
• W2947405510 cites W2136871952 @default.
• W2947405510 cites W2140114661 @default.
• W2947405510 cites W2142845582 @default.
• W2947405510 cites W2145110081 @default.
• W2947405510 cites W2159584694 @default.
• W2947405510 cites W2163196794 @default.
• W2947405510 cites W2170938637 @default.
• W2947405510 cites W2216468827 @default.
• W2947405510 cites W2284327277 @default.
• W2947405510 cites W2503546263 @default.
• W2947405510 cites W2546466212 @default.
• W2947405510 cites W2766842037 @default.
• W2947405510 cites W4245231203 @default.
• W2947405510 doi "https://doi.org/10.1158/1078-0432.ccr-18-2108" @default.
• W2947405510 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6697573" @default.
• W2947405510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31142501" @default.
• W2947405510 hasPublicationYear "2019" @default.
• W2947405510 type Work @default.
• W2947405510 sameAs 2947405510 @default.
• W2947405510 citedByCount "27" @default.
• W2947405510 countsByYear W29474055102020 @default.
• W2947405510 countsByYear W29474055102021 @default.
• W2947405510 countsByYear W29474055102022 @default.
• W2947405510 countsByYear W29474055102023 @default.
• W2947405510 crossrefType "journal-article" @default.
• W2947405510 hasAuthorship W2947405510A5000921376 @default.
• W2947405510 hasAuthorship W2947405510A5005521067 @default.
• W2947405510 hasAuthorship W2947405510A5006315280 @default.
• W2947405510 hasAuthorship W2947405510A5015153331 @default.
• W2947405510 hasAuthorship W2947405510A5015697739 @default.
• W2947405510 hasAuthorship W2947405510A5024285638 @default.
• W2947405510 hasAuthorship W2947405510A5028975540 @default.

• next